• EMD638683: From SGK1 Target to Cell Phenotype

  2026-09-16

  Explore how EMD638683, an SGK1 inhibitor, connects SGK signaling with endothelial stiffness, NDRG1 phosphorylation, and tumor-cell responses. This guide emphasizes assay interpretation, pharmacological selectivity, and practical decisions that distinguish target engagement from downstream phenotype.

• Large-Scale Gastruloid Arrays for Phenotype Screening

  2026-09-16

  Jan and colleagues developed an indexed magnetic microraft platform that enables imaging, phenotyping, and automated sorting of individual human gastruloids at scale. The study shows that the system can resolve euploid–aneuploid differences and connect image-derived phenotypes with spatial-patterning gene expression, creating a practical framework for developmental screening.

• p21-ELP1-Bac Delivery Suppresses Glioblastoma Growth

  2026-09-15

  The reference study shows that an elastin-like polypeptide and cell-penetrating peptide can deliver a p21-derived inhibitor into three glioblastoma models and suppress proliferation primarily through cytostatic effects. Its findings support intracellular peptide delivery as a strategy for restoring cell-cycle control while highlighting lineage-dependent sensitivity and the need for in vivo validation.

• Telatinib and the Next Edge in Angiogenesis Research

  2026-09-15

  Telatinib (BAY 57-9352) offers translational researchers a mechanism-aware way to study angiogenesis, invasion, and kinase-driven resistance. This article interprets recent HER2–VEGFR2 findings in triple-negative breast cancer, positions Telatinib within a multitarget research strategy, and outlines assays that can distinguish pathway engagement from nonspecific cytotoxicity.

• Cepharanthine Inhibits Endometriosis Growth

  2026-09-14

  This 2026 study evaluates the biscoclaurine alkaloid Cepharanthine across immortalized stromal cells, patient-derived endometrial organoids, and a murine peritoneal endometriosis model. Its main contribution is a cross-model mechanism linking reduced lesion growth with G0/G1 arrest, DNA damage, impaired DNA repair, and apoptosis.

• Amyloid Beta-Peptide (1-40): State-Aware Assays

  2026-09-14

  Amyloid Beta-Peptide (1-40) (human) is more than a generic neurotoxicity reagent: its molecular state can determine the biological question an assay answers. This guide combines product chemistry with a microglial signaling study to build more discriminating Alzheimer’s disease research workflows.

• In Vitro Drug Response Evaluation in Cancer

  2026-09-13

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability to separate proliferative arrest from drug-induced cell death. Its central contribution is a more interpretable framework for designing and reporting cancer drug-response experiments, with implications for targeted and anti-angiogenic studies.

• Thermal-Protective Hydrogel for Curative Tumor Ablation

  2026-09-12

  The reference study develops MR@CaP@HA, an injectable hydrogel that combines local thermal insulation with pH- and glutathione-responsive delivery of mitoxantrone and Resiquimod (R-848) during radiofrequency ablation. By protecting adjacent tissue while strengthening immunogenic cell death and innate immune response modulation, the platform improved residual-tumor control and achieved complete tumor eradication in a subset of treated animals.

• MK-0812: Deconvolving Gut–Liver Inflammation

  2026-09-11

  MK-0812 enables selective CCR2 interrogation in monocyte trafficking and MASH research. This article translates intestinal TM6SF2 findings into a compartment-resolved assay strategy that separates epithelial disease initiation from hepatic immune recruitment.

• Reversine Workflow for Aurora Kinase Studies

  2026-09-11

  Build a controlled Reversine workflow that links Aurora kinase inhibition to mitotic failure, proliferation loss, and apoptosis. Extend the same assay logic from cancer cell models to single-gastruloid phenotyping while preserving clear boundaries between established evidence and exploratory applications.

• Humanized Mice Improve HD56 Prodrug PK Prediction

  2026-09-10

  The 2025 Drug Metabolism and Disposition study shows that humanized-liver mice can resolve species-dependent metabolism of the carboxylate ester prodrug HD56 and improve prediction of its conversion to HD561. By integrating permeability, enzyme phenotyping, microsomal stability, plasma studies, pharmacokinetics, and in vivo–in vitro correlation, the work provides a practical framework for evaluating ester prodrugs before clinical development.

• Telatinib: From Target Profile to Causal Assays

  2026-09-10

  Telatinib (BAY 57-9352) is a multitarget kinase inhibitor for dissecting VEGFR, c-Kit, and PDGFR signaling in cancer models. This article translates its target breadth and breast cancer evidence into a causal, mechanism-aware assay strategy rather than a simple viability workflow.

• Ceftolozane/Tazobactam: Innovation, Evidence, and Limits

  2026-09-09

  The reference review explains how ceftolozane/tazobactam combines potent antipseudomonal cephalosporin activity with beta-lactamase inhibition to address resistant gram-negative infections. Its most important practical insights concern PBP targeting, time-dependent pharmacodynamics, renal elimination, and the limits of extrapolating activity across resistance mechanisms.

• Cathepsin B inhibitor CA-074: Practical Guide

  2026-09-09

  Cathepsin B inhibitor CA-074 (SKU A1926) provides a selective tool for testing cathepsin B activity in biochemical, cell-based, cancer metastasis, neurotoxicity, and immune-response workflows. It should be used with vehicle, viability, and target-engagement controls; dossier observations should not be generalized to every cell type, disease model, or cathepsin-dependent phenotype.

• How Kinase Conformation Drives p38α Dephosphorylation

  2026-09-08

  A bioRxiv preprint shows that some p38α inhibitors do more than occupy the kinase active site: they also expose the activation-loop phosphothreonine to the phosphatase WIP1. By linking inhibitor binding, kinase conformation, and dephosphorylation kinetics, the study introduces a framework for designing inhibitors that combine direct kinase blockade with phosphatase-facilitated signal termination.

7931 records 1/529 page Next 12345 下5页 Last page